Dexamethasone

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.4. Hormones and antihormones

EMLc | Codes ATC: H02AB02

Indication	Burkitt lymphoma including Burkitt leukaemia — Code ICD11: 2A85.6
INN	Dexamethasone
Type de médicament	Chemical agent
Type de liste	Liste complémentaire
Formulations	**Oral > Liquid:** 2 mg per 5 mL (as sodium phosphate) (EMLc) **Parenteral > General injections > unspecified:** 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) **Oral > Solid > tablet:** 2 mg (as dexamethasone base) (EMLc) ; 4 mg (as dexamethasone base)
Historique des statuts LME	Ajouté pour la première fois en 2021 (TRS 1035) Modifié en 2025 (TRS 1064)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Balises	Cancer
Wikipédia	Dexamethasone
DrugBank	Dexamethasone

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.